Assessment of current biomarkers and interventions to identify and treat women at risk of preterm birth.

biomarkers interventions limitations preterm birth screening tools

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2024
Historique:
received: 08 04 2024
accepted: 15 07 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 12 8 2024
Statut: epublish

Résumé

Preterm birth remains an important global problem, and an important contributor to under-5 mortality. Reducing spontaneous preterm birth rates at the global level will require the early identification of patients at risk of preterm delivery in order to allow the initiation of appropriate prophylactic management strategies. Ideally these strategies target the underlying pathophysiologic causes of preterm labor. Prevention, however, becomes problematic as the causes of preterm birth are multifactorial and vary by gestational age, ethnicity, and social context. Unfortunately, current screening and diagnostic tests are non-specific, with only moderate clinical risk prediction, relying on the detection of downstream markers of the common end-stage pathway rather than identifying upstream pathway-specific pathophysiology that would help the provider initiate targeted interventions. As a result, the available management options (including cervical cerclage and vaginal progesterone) are used empirically with, at best, ambiguous results in clinical trials. Furthermore, the available screening tests have only modest clinical risk prediction, and fail to identify most patients who will have a preterm birth. Clearly defining preterm birth phenotypes and the biologic pathways leading to preterm birth is key to providing targeted, biomolecular pathway-specific interventions, ideally initiated in early pregnancy Pathway specific biomarker discovery, together with management strategies based on early, mid-, and-late trimester specific markers is integral to this process, which must be addressed in a systematic way through rigorously planned biomarker trials.

Identifiants

pubmed: 39131090
doi: 10.3389/fmed.2024.1414428
pmc: PMC11312378
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1414428

Informations de copyright

Copyright © 2024 Gravett, Menon, Tribe, Hezelgrave, Kacerovsky, Soma-Pillay, Jacobsson and McElrath.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Michael G Gravett (MG)

Department of Obstetrics and Gynecology and of Global Health, University of Washington, Seattle, WA, United States.

Ramkumar Menon (R)

Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, United States.

Rachel M Tribe (RM)

Department of Women and Children's Health, Faculty of Life Sciences and Medicine, School of Life Course Sciences, St Thomas' Hospital Campus, King's College London, London, United Kingdom.

Natasha L Hezelgrave (NL)

Department of Women and Children's Health, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, United Kingdom.

Marian Kacerovsky (M)

Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Department of Obstetrics and Gynecology, Faculty of Medicine Hradec Kralove, Charles University in Prague, Hradec Kralove, Czechia.

Priya Soma-Pillay (P)

Department of Obstetrics and Gynaecology, The University of Pretoria School of Medicine, Pretoria, South Africa.

Bo Jacobsson (B)

Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Genetics and Bioinformatics, Domain of Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway.

Thomas F McElrath (TF)

Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Classifications MeSH